Tag:
Silence Therapeutics
Latest Headlines
Latest Headlines
Silence Therapeutics inks deal to deliver 'master switches' to shut down cancer
Silence Therapeutics has found a new partner in need of help reaching specific cells with RNA-targeted drugs. Mirna Therapeutics has signed on to use two of U.K.-based Silence's lipid delivery
U.K.'s Silence grabs RNAi delivery deal with Big Pharma
Silence Therapeutics has struck a deal to help a Big Pharma outfit deliver gene-silencing drugs to lung tissues. The deal shows that large drugmakers are pursuing new projects in the troubled RNAi
Silence says it's been approached by mystery suitor
London-based Silence Therapeutics says an unnamed suitor has made an overture that could lead to a buyout offer--the second time in the last year that Silence has discussed a potential deal with a
Silence Therapeutics shouts about RNAi tech
Silence Therapeutics is making a lot of noise these days when it comes to taking advantage of key IP and partnerships in the London-based company's RNA interference (RNAi) technology. The latest is a
Silence and Intradigm merge RNAi forces, flag deals
Two small RNAi players are merging forces in hopes of attracting some increased attention from the Big Pharma coaches calling the partnership plays. The UK's Silence Therapeutics will issue $26
Silence Therapeutics plots reverse takeover with mystery suitor
London-based Silence Therapeutics confirmed this morning that it is in merger talks with an unidentified company. And Silence, a prominent RNAi developer, says it expects the deal to be handled as a
Silence gets green light for siRNA trial
The UK's Silence Therapeutics has won regulatory approval to begin an early-stage human trial that will for the first time test the infusion of one of its gene silencing therapies directly to the
Quark prepares for human trials of siRNA therapy
Quark Pharmaceuticals says the FDA has approved its IND application for DGFi, an experimental siRNA drug for kidney transplant patients. "We are pleased with the FDA acceptance of our DGFi IND
